News

Sabine Taschner-Mandl is elected to the executive board of Europe’s neuroblastoma network SIOPEN Developing new therapies for childhood nerve tumors and identifying more molecular markers for better diagnosis – this is what Sabine Taschner-Mandl strives for in her new role as Executive Committee Board Member of the European Neuroblastoma Research Group SIOPEN. Sabine Taschner-Mandl, PhD, […]

Childhood cancer is different from cancer in adults. Thus, it needs research specifically tailored to pediatric tumors, which requires dedicated funding. The need for medicines suitable for children, as well as improvements in long-term follow-up care for cancer survivors have been discussed with EU Health Commissioner Stella Kyriakides, M.Ed., and Austrian Health Minister Wolfgang Mückstein,

Kaan Boztug awarded the “Işil Berat Barlan Award for Primary Immunodeficiency Diseases” The scientist receives this award for his pioneering research on immunodeficiencies. Disturbances in the balance of the immune system can be the starting point for a number of diseases such as increased susceptibility to infections, autoimmune diseases and cancer. The study of congenital

Bone marrow metastases for the first time analyzed cell by cell When childhood nerve tumors, so-called neuroblastomas, form metastases, they preferentially do so in the bone marrow. A study by St. Anna Children’s Cancer Research Institute shows for the first time the exact cell composition of such metastases. This knowledge forms the basis for the

Four FWF Stand Alone Projects recently approved at St. Anna CCRI The Austrian Science Fund (FWF) awards four scientists from St. Anna Children’s Cancer Research Institute (St. Anna CCRI) with Stand Alone Grants, each of which is worth almost € 400,000. Congratulations to the grantees Kaan Boztug, Eva König, Thomas Lion, and Eleni Tomazou! Getting

Nerve tumor in children: study identifies better tolerable chemotherapy without loss of efficacy The initial chemotherapy of aggressive childhood nerve tumors, so-called high-risk neuroblastomas, is crucial for ultimate survival. It has now been shown that the chemotherapy regimen used by the European Neuroblastoma Study Group is equally efficacious but better tolerated than a highly effective

Do you speak immunology? A new language for congenital immune disorders A detailed vocabulary to identify and explore rare, congenital immune disorders around the world? That is exactly what is now available thanks to a new study led by the Ludwig Boltzmann Institute for Rare and Undiagnosed Diseases in Vienna and the University Medical Center

“1000 Ideas” to boost childhood cancer research: St. Anna CCRI earns two grants in competitive FWF program Two projects from St. Anna Children’s Cancer Research Institute (St. Anna CCRI) receive funding from the “1000 Ideas Programme” of the Austrian Science Fund (FWF). The aim of this program is to support daring and original research ideas

Hot off the press: a new role for histone modifications in genomic imprinting Imprinted genes are expressed from either the paternal or maternal allele. Reporting in Nature Communications, scientists led by Martin Leeb have now discovered 71 previously unrecognized imprinted genes in preimplantation blastocysts. The study found that imprinting created by differential histone marks plays

Pediatric high-risk tumors: gene defect shortens survival and needs targeted treatment Neuroblastomas, the most common solid tumors outside the brain in children, are associated with poorer survival if they have genetic alterations in the ALK gene and belong to the high-risk group. This was shown by scientists from St. Anna Children’s Cancer Research institute together

St. Anna Children’s Cancer Research Institute is receiving a prestigious Life Science Grant for Precision Medicine, provided by the Vienna Science and Technology Fund (WWTF). Award winner Eleni Tomazou and her colleagues will clinically validate a promising new diagnostic approach, expected to enable precision medicine in childhood tumors based on blood samples.

Blood test detects childhood tumors based on their epigenetic profiles A new study exploits the characteristic epigenetic signatures of childhood tumors to detect, classify and monitor the disease. The scientists analyzed short fragments of tumor DNA that are circulating in the blood. These “liquid biopsy” analyses exploit the unique epigenetic landscape of bone tumors and

Invasive virus infections during chemotherapy: an underestimated factor While the importance of virus infections as a leading cause of morbidity and mortality is well documented in patients undergoing allogeneic stem cell transplantation, their impact in cancer patients receiving chemotherapy is less well studied. A new publication reveals that invasive viral infections can be clinically relevant

The project “Tracking the origin of Ewing sarcoma (…)” coordinated by St. Anna Children’s Cancer Research Institute, has been selected for the prestigious Crazy 8 Initiative Award. With this funding, Viennese scientists aim to elucidate the still unsolved mystery of the origin and development process of pediatric bone sarcomas. This knowledge is fundamental to lay a path for new and more effective therapies to cure childhood cancer.